PremiumCompany AnnouncementsMoleculin Biotech Advances Clinical Trials Amid Financial Losses Promising Advancements in Moleculin Biotech’s Annamycin Pivotal Trial Drive Buy Rating and $8 Price Target Moleculin Biotech Shares Corporate Presentation Update PremiumThe FlyMoleculin Biotech target adjusted to $8 from $45 at H.C. Wainwright Biotech Alert: Searches spiking for these stocks today Moleculin Biotech announces pricing of $3.5M registered direct offering PremiumThe FlyMoleculin Biotech receives first approval in Europe for AML trial recruiting Moleculin Biotech Launches MIRACLE Study for AML Moleculin Biotech Shares Updates on MIRACLE Trial 
